Drugs / Moist exposed burn ointment
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04153032 | Dec 2019 → Jan 2026 overdue | — | American University of Beirut Medical Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Moist exposed burn ointment | “Moist exposed burn ointment (MEBO) is an ointment that is effective for the treatment of burns and wound healing and is becoming popular in the treatment of anal fissures.” PMID 33627111 ↗ Feb 2021 |
| Known as | MEBO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04153032 ↗ |
| Route | Topical | “The first group of patients will apply MEBO ointment peri-anally 3 times daily for 6 weeks.” NCT04153032 ↗ |